Beata Maćkowiak-Matejczyk

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Susana Banerjee, Amit M. Oza, Michael J. Birrer et al. · Annals of Oncology · 2018 · 91 citations · Full text

Pegylated Liposomal Doxorubicin, Oncology, Medicine +9

Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer

Bożena Dobrzycka, Beata Maćkowiak-Matejczyk, Katarzyna M. Terlikowska et al. · European Cytokine Network · 2013 · 78 citations

Prognostic Factors, Prognostic Biomarkers, Oncology +15

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses

Katarzyna M. Terlikowska, Bożena Dobrzycka, Anna Maria Witkowska et al. · Journal of Ovarian Research · 2016 · 49 citations · Full text

518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation

A.M. Oza, A.S. Lisyanskaya, A.A. Fedenko et al. · Annals of Oncology · 2022 · 39 citations

Relapsed Ovarian Carcinoma, Rucaparib Vs Chemotherapy, Medicine +9

Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma

Bożena Dobrzycka, Beata Maćkowiak-Matejczyk, Katarzyna M. Terlikowska et al. · Tumor Biology · 2015 · 33 citations · Full text